Izraelis - anglų - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - powder for inhalation - budesonide micronized 160 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - asthmasymbicort turbuhaler 160/4.5 mcg/dose is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations.chronic obstructive pulmonary disease (copd)symbicort turbuhaler 160/4.5 mcg/dose is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev1) < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy.

Airija - anglų - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - formoterol fumarate dihydrate; budesonide - inhalation powder - 400 µg /12 µg/inhalation - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide - adrenergics and other drugs for obstructive airway diseases. - it is indicated: in adults and adolescents aged 12 to 17 years for the regular treatment of asthma where use of a combination is appropriate; in adults, aged 18 years and older, for the symptomatic treatment of patients with severe copd and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators

Europos Sąjunga - anglų - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive - formoterol and glycopyrronium bromide - bevespi aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Kenija - anglų - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - formoterol fumarate dihydrate ph. eur. &… - inhalation vapour, powder - formoterol fumarate dihydrate 6 mcg/ dose &… - adrenergics inhalants: adrenergics and other

Kenija - anglų - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - formoterol fumarate dihydrate ph. eur. &… - inhalation vapour, powder - formoterol fumarate dihydrate 6 mcg/ dose &… - adrenergics inhalants: adrenergics and other

Kenija - anglų - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - formoterol fumarate dihydrate ph. eur. &… - inhalation vapour, powder - formoterol fumarate dihydrate 6 mcg/ dose &… - adrenergics inhalants: adrenergics and other

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - breyna is indicated for the treatment of asthma in patients 6 years of age and older. breyna should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long-acting beta2 -adrenergic agonist (laba). important limitations of use: breyna 160 mcg/4.5 mcg is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema. breyna 160 mcg/4.5 mcg is also indicated to reduce exacerbations of copd. breyna 160 mcg/4.5 mcg is the only strength indicated for the treatment of copd. important limitations of use: the use of breyna is contraindicated in the following conditions: there are no adequate and well-controlled studies of budesonide and formoterol fumarate dihydrate inhalation aerosol or one of its individual components, formoterol fumarate, in pre

Izraelis - anglų - Ministry of Health

abic marketing ltd, israel - budesonide micronized; formoterol fumarate dihydrate - powder for inhalation - formoterol fumarate dihydrate 4.5 mcg/dose; budesonide micronized 160 mcg/dose - formoterol and budesonide - asthmaduoresp spiromax 160/4.5 mcg/dose is indicated in adults and adolescents (12 years and older), for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor agonist) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting β2 adrenoceptor agonists.orpatients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptor-agonists.chronic obstructive pulmonary disease (copd)duoresp spiromax 160/4.5 mcg/dose is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev1)< 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy

Airija - anglų - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - formoterol fumarate - inhalation powder, hard capsule - 12 microgram(s) - selective beta-2-adrenoreceptor agonists; formoterol

Airija - anglų - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - formoterol fumatrate dihydrate - powder for inhalation - 6 microgram(s) - selective beta-2-adrenoreceptor agonists; formoterol